Articles related to RESEARCH & CLINICAL TRIALS

Boehringer Ingelheim’s SYNCHRONIZE-1 phase 3 trial reported 16.6% average body weight reduction with survodutide, a dual GLP-1/glucagon receptor agonist, over 76 weeks in adults without type 2 diabetes.

A novel oral extended-release minoxidil formulation produced significantly greater non-vellus hair counts and patient-reported coverage improvement than placebo in men with androgenetic alopecia at six months.

Brain MRI patterns differed enough between first and second pregnancies that a machine learning classifier could distinguish them, with the default mode network shift appearing to be a first-pregnancy-dominant adaptation.

A GLP-1 receptor agonist delivered directly into the knee joint received FDA Fast Track designation for osteoarthritis with synovitis, with phase 2a data not expected until 2027.

Switching Parkinson’s patients to Crexont added more than three hours of daily symptom control in interim Phase 4 data. Here’s how to read an open-label, sponsor-run signal.

The OSPREY trial puts proximal hypoglossal nerve stimulation on the map for moderate-to-severe OSA, with strong short-term numbers and the limitations a small unblinded RCT carries.